Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Conditions

• Primary Open Angle Glaucoma or Ocular Hypertension

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Netarsudil Ophthalmic Solution 0.02% — DRUG
  1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
• Placebo Comparator — OTHER
  1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye

Study Details

To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo

Key Dates

Start date

Oct 20, 2017

Status verified

Jul 2019

Primary completion

Apr 19, 2018

Completion

Apr 19, 2018

Study Design

Enrollment

20 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Netarsudil Ophthalmic Solution 0.02%
  Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
• Placebo Comparator: Placebo Comparator
  Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye

Primary Outcome Measure

Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility [ Time Frame: Study treatment was administered for 7 days, and outcome measures collected on Day 8 ]

Locations (2)

Find similar trials in Rochester, MN

Related Studies

• A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
  Recruiting · Brian Shafer · Plymouth Meeting, Pennsylvania